Fennec Pharmaceuticals
FENC
56 hedge funds and large institutions have $169M invested in Fennec Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 13 reducing their positions, and 6 closing their positions.
31,400% more call options, than puts
Call options by funds: $630K | Put options by funds: $2K
77% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 13
57% more capital invested
Capital invested by funds: $108M → $169M (+$61.7M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
2.76% more ownership
Funds ownership: 53.88% → 56.64% (+2.8%)
2% more funds holding
Funds holding: 55 → 56 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.77M |
| 2 |
Morgan Stanley
New York
|
+$926K |
| 3 |
BlackRock
New York
|
+$742K |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$545K |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$405K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Solas Capital Management
Darien,
Connecticut
|
-$2.88M |
| 2 |
6CM
683 Capital Management
New York
|
-$1.33M |
| 3 |
DCM
DG Capital Management
New York
|
-$559K |
| 4 |
ACA
Apis Capital Advisors
New York
|
-$526K |
| 5 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$366K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MLICM
51
Metropolitan Life Insurance Company (MetLife)
New York
| $11.3K | – | – | – |
|
52
Osaic Holdings
Scottsdale,
Arizona
| $1.23K | – | – | – |
|
53
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $976 | +$721 | +87 | New |
|
54
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| $942 | +$157 | +19 | +29% |
|
55
Russell Investments Group
London,
United Kingdom
| $539 | -$2.26K | -273 | -85% |
|
|
ACA
56
Apis Capital Advisors
New York
| – | -$526K | -70,000 | Closed |
|
|
BCM
57
Bridgeway Capital Management
Houston,
Texas
| – | -$257K | -34,200 | Closed |
|
58
Citadel Advisors
Miami,
Florida
| – | -$114K | -13,710 | Closed |
|
59
Allspring Global Investments
Charlotte,
North Carolina
| – | -$50.4K | -6,705 | Closed |
|
|
HWM
60
HighMark Wealth Management
St. Paul,
Minnesota
| – | -$22.5K | -3,000 | Closed |
|
|
BTI
61
Blue Trust Inc
Alpharetta,
Georgia
| – | -$21K | -2,367 | Closed |
|
62
Simplex Trading
Chicago,
Illinois
| – | +$99 | +12 | New |
|
FENC Hedge Fund Activity: Q4 2023 in Review
56 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q4 2023, worth a combined $169M — up 57% from $108M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new FENC positions and 6 closed out — a net gain of 1 holder — while 23 added to existing stakes and 13 trimmed.
The largest buyer was Vanguard Group, adding an estimated $8.77M. The largest seller was Solas Capital Management, cutting an estimated $2.88M.
- 56 institutional investors held Fennec Pharmaceuticals (FENC) as of Q4 2023, up from 55 in Q3 2023.
- Funds reported $169M of Fennec Pharmaceuticals stock for Q4 2023, up 57% quarter-over-quarter.
- 7 funds opened new Fennec Pharmaceuticals positions in Q4 2023 and 6 closed out, a net change of +1 holder.
- The largest Fennec Pharmaceuticals buyer in Q4 2023 was Vanguard Group, an estimated $8.77M added.
- The largest Fennec Pharmaceuticals seller in Q4 2023 was Solas Capital Management, an estimated $2.88M sold.
Based on aggregated 13F filings for Q4 2023.